- Home
- RPD vs KYMR Comparison
RPD vs KYMR Comparison
Compare RPD & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPD
- KYMR
- Stock Information
- Founded
- RPD 2000
- KYMR 2015
- Country
- RPD United States
- KYMR United States
- Employees
- RPD N/A
- KYMR N/A
- Industry
- RPD Computer Software: Prepackaged Software
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- RPD Technology
- KYMR Health Care
- Exchange
- RPD Nasdaq
- KYMR Nasdaq
- Market Cap
- RPD 1.8B
- KYMR 2.2B
- IPO Year
- RPD 2015
- KYMR 2020
- Fundamental
- Price
- RPD $27.59
- KYMR $29.62
- Analyst Decision
- RPD Buy
- KYMR Buy
- Analyst Count
- RPD 20
- KYMR 13
- Target Price
- RPD $40.67
- KYMR $56.69
- AVG Volume (30 Days)
- RPD 946.1K
- KYMR 591.0K
- Earning Date
- RPD 05-06-2025
- KYMR 05-01-2025
- Dividend Yield
- RPD N/A
- KYMR N/A
- EPS Growth
- RPD N/A
- KYMR N/A
- EPS
- RPD 0.40
- KYMR N/A
- Revenue
- RPD $844,007,000.00
- KYMR $47,072,000.00
- Revenue This Year
- RPD $3.61
- KYMR $44.93
- Revenue Next Year
- RPD $4.82
- KYMR N/A
- P/E Ratio
- RPD $68.98
- KYMR N/A
- Revenue Growth
- RPD 8.53
- KYMR N/A
- 52 Week Low
- RPD $26.77
- KYMR $29.07
- 52 Week High
- RPD $50.55
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- RPD 35.80
- KYMR 33.94
- Support Level
- RPD $27.50
- KYMR $29.83
- Resistance Level
- RPD $29.92
- KYMR $35.28
- Average True Range (ATR)
- RPD 1.14
- KYMR 1.79
- MACD
- RPD 0.33
- KYMR -0.20
- Stochastic Oscillator
- RPD 19.62
- KYMR 4.54
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.